Baxter Gains FDA Clearance for Bone Graft Substitute
Baxter International received FDA 510(k) clearance for its Actifuse Flow bone graft substitute. ...
Sep 07, 2018,
Orthobiologics
ORTHOFLASHHistogenics’ Top-Line Results From Phase 3 Trial of NeoCart
Histogenics' Phase III clinical trial of NeoCart® tissue engineered implant did not meet the primary endpoint of a statistically significant improvement in pain...
Sep 06, 2018,
CartiHeal Performs First Belgian Case in Agili-C Study
CartiHeal announced successful enrollment of the first Belgian patient in the Agili-C IDE pivotal study....
Aug 29, 2018,
First U.S. Patients Receive Agili-C Implants
CartiHeal announced successful enrollment of the first two U.S. patients in the Agili-C IDE pivotal study....
Aug 17, 2018,
BONESUPPORT’s CERAMENT G Approved by Health Canada
BONESUPPORT received regulatory approval from Health Canada for CERAMENT® G gentamicin-eluting injectable ceramic bone graft substitute....
Aug 16, 2018,
Cerapedics Enrolls Patients in IDE Study of P-15L Bone Graft in TLIF
Cerapedics enrolled the first patients in an IDE clinical trial evaluating P-15L Bone Graft vs. autograft in TLIF....
Jul 30, 2018,
Wright Medical Launches PROstep and AUGMENT Injectable
Wright Medical commenced U.S. launch of the PROstep Minimally Invasive Surgery System and AUGMENT® Injectable Bone Graft....
Jul 11, 2018,
Kuros Biosciences Reports First US and UK Sales of MagnetOs
Kuros Biosciences announced the first commercial uses of MagnetOs bone graft substitute in the U.S. and U.K....
Jul 09, 2018,
Lipogems Gains FDA Clearance for Adipose Tissue Transplant
Lipogems received FDA 510(k) clearance to market a Microfragmented Adipose Tissue Transplant system for use in orthopaedic and arthroscopic procedures. ...
Jul 09, 2018,
Anika Therapeutics Announces Top-Line Results from CINGAL Trial in Knee OA
In the Phase III 16-02 clinical trial of Anika Therapeutics' CINGAL, statistically significant results in pain reduction were not demonstrated...
Jun 20, 2018,
Loading new posts...
No more posts
